펩타이드 약물 접합체의 최신 동향

Recent Advances in Peptide-Drug Conjugates

Peptide-drug conjugates (PDCs) are an emerging class of targeted drug delivery system. Compared to antibody-drug conjugates (ADCs), PDCs offer distinct advantages, including improved tissue permeability, simple synthesis, and lower immunogenicity. However, despite their high therapeutic potential, the clinical development of PDCs is often hindered by issues such as structural instability and short circulation half-life. As of 2025, with two approved products, [177Lu]Lu-DOTA-TATE and melphalan flufenamide, and 11 PDCs are undergoing clinical trials. In this review, PDCs are categorized based on peptide design strategies, and their therapeutic indications, pharmacokinetic profiles, and clinical outcomes are systematically analyzed. This approach highlights the potential of PDCs to provide enhanced efficacy with reduced systemic toxicity in targeted cancer therapy.